logo-loader
viewBioPorto

BioPorto maintains sales momentum of NGAL test, begins patient enrollment for coronavirus test

BioPorto Diagnostics A/S (CPH:BIOPOR) CEO Peter Eriksen tells Proactive in its third quarter, NGAL Test revenue was up 17% compared to the same quarter last year, proving that revenue from the test has not been affected by delays caused by the coronavirus pandemic.

Eriksen says what's more, the Danish group will begin enrolling patients for its COVID-19 rapid test trial, data to be used for the group's Emergency Use Authorization, which BioPorto is planning to submit to the FDA.

Quick facts: BioPorto

Price: 0.4 USD

PINK:THOXF
Market: PINK
Market Cap: $106.63 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BioPorto named herein, including the promotion by the Company of BioPorto in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: BioPorto reveals 'healthy growth' in second quarter revenue

BioPorto A/S (CPH:BIOPOR) CFO Ole Larsen tells Proactive the diagnostic company saw "healthy growth" in revenue for the second quarter, where revenue grew by 10% to DKK (Danish Krone) 7.8 million (US$1.16 million) compared to DKK 7.2 million (US$1.08 million) in the same period in the previous...

on 15/8/19

2 min read